Topoisomerase II inhibitors, irrespective of their chemical composition, ameliorate experimental arthritis

Rheumatology

Volumn 44, Issue 2, 2005, Pages 183-186

  Verdrengh, Margareta ^a   Isaksson, O ^a   Tarkowski, A ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Collagen induced arthritis; Topoisomerase II inhibitor

Indexed keywords

COLLAGEN ANTIBODY; COLLAGEN TYPE 2; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; GYRASE INHIBITOR; MITOXANTRONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; AUTOIMMUNITY; CHEMICAL COMPOSITION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG MEGADOSE; ENZYME INHIBITION; HISTOLOGY; IMMUNIZATION; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODY FORMATION; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; COLLAGEN TYPE II; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ETOPOSIDE; IMMUNIZATION; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-6; MALE; MICE; MICE, INBRED DBA; MITOXANTRONE; NUCLEIC ACID SYNTHESIS INHIBITORS;

EID: 14044273745     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh444     Document Type: Article

References (22)

1. Myers LK, Rosloniec EF, Cremer MA, Kang AH. Collagen-induced arthritis, an animal model of autommumity. Life Sci 1997;61:1861-78.
2. Holmdahl R, Bockermann R, Backlund J, Yamada H. The molecular pathogenesis of collagen-induced arthritis in mice - a model for rheumatoid arthritis. Ageing Res Rev 2002;1:135-47.
3. Boos G, Stopper H. Genotoxicity of several clinically used topoisomerase II inhibitors. Toxicol Lett 2000;116:7-16.
4. Gonsette RE. Mitoxantrone in progressive multiple sclerosis: when and how to treat? J Neurol Sci 2003;206:203-8.
5. van't Wout JW, Linde I, Leijh PC, van Furth R. Effect of irradiation, cyclophosphamide, and etoposide (VP-16) on number of peripheral blood and peritoneal leukocytes in mice under normal conditions and during acute inflammatory reaction. Inflammation 1989;13:1-14.
6. Calame W, Douwes-Idema AE, van den Barselaar MT, van Furth R, Mattie H. Influence of cytostatic agents on the pulmonary defence of mice infected with Klebsiella pneumoniae and on the efficacy of treatment with ceftriaxone. J Infect 1994;29:53-66.
7. Verdrengh M, Jonsson IM, Zaether O, Bajtner E, Holmdahl R, Tarkowski A. Total abrogation of collagen II-induced arthritis and the B cell response to type II collagen using suboptimal doses of a topoisomerase II antagonist. Ann Rheum Dis 2002;61:829-31.
8. Gokhale PC, Pei J, Zhang C, Ahmad I, Rahman A, Kasid U. Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone. Anticancer Res 2001;21:3313-21.
9. Noviello E, Cimoli G, Cosimi A et al. Tumour necrosis factor enhances the therapeutic effect of mitoxantrone in human ovarian cancer xenograft. Cytokine 1996;8:330-3.
10. Abdelnour A, Arvidson S, Bremell T, Ryden C, Tarkowski A. The accessory gene regulator (agr) controls Staphylococcus aureus virulence in a murine arthritis model. Infect Immun 1993;61:3879-85.
11. Verdrengh M, Tarkowski A. Impact of topoisomerase II inhibition on cytokine and chemokine production. Inflamm Res 2003;52:148-53.
12. Bremell T, Abdelnour A, Tarkowski A. Histopathological and serological progression of experimental Staphylococcus aureus arthritis. Infect Immun 1992;60:2976-85.
13. Smith MD, Walker JG. Apoptosis a relevant therapeutic target in rheumatoid arthritis? Rheumatology 2004;43:405-7.
14. Sato K, Taniguchi T, Suzuki M, Shinohara F, Takada H, Rikiishi H. Dual role of NF-kappa B in apoptosis of THP-1 cells during treatment with etoposide and lipopolysaccharide. Leuk Res 2004;28:63-9.
15. Boland MP, Fitzgerald KA, O'Neill LA. Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells. J Biol Chem 2000;275:25231-8.
16. Szmigielska-Kaplon A, Ciesielska E, Szmigiero L, Robak T. Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro. Eur J Haematol 2002;68:370-5.
17. Uson J, Balsa A, Pascual-Salcedo D et al. Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies. J Rheumatol 1997;24:2069-75.
18. Sasai M, Saeki Y, Ohshima S et al. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum 1999;42:1635-43.
19. Lublin FD, Lavasa M, Viti C, Knobler RL. Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin Immunol Immunopathol 1987;45:122-8.
20. Svensson L, Jirholt J, Holmdahl R, Jansson L. B cell-deficient mice do not develop type II collagen-induced arthritis (CIA). Clin Exp Immunol 1998;111:521-6.
21. Holmdahl R, Jansson L, Larsson A, Jonsson R. Arthritis in DBA/1 mice induced with passively transferred type II collagen immune serum. Immunohistopathology and serum levels of anti-type II collagen auto-antibodies. Scand J Immunol 1990;31:147-57.
22. Fidler JM, DeJoy SQ, Gibbons JJ, Jr. Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J Immunol 1986;137:727-32.